Akebia Therapeutics, Inc.盘中异动快速下挫5.12%报1.21美元

自选股智能写手07-12

北京时间2024年07月12日23时23分，Akebia Therapeutics, Inc.（AKBA.us）股票出现波动，股价大幅跳水5.12%。截至发稿，该股报1.21美元/股，成交量237.982万股，换手率1.14%，振幅10.24%。最近的财报数据显示，该股实现营业收入32.61百万美元，净利润-17.99百万美元，每股收益-0.09美元，毛利20.64百万美元，市盈率-5.52倍。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2450253710?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-12 23:23","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2450253710","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics, Inc.盘中异动 快速下挫5.12%报1.21美元","media":"自选股智能写手","content":"<div>\n<p>北京时间2024年07月12日23时23分，Akebia Therapeutics, Inc.（AKBA.us）股票出现波动，股价大幅跳水5.12%。截至发稿，该股报1.21美元/股，成交量237.982万股，换手率1.14%，振幅10.24%。最近的财报数据显示，该股实现营业收入32.61百万美元，净利润-17.99百万美元，每股收益-0.09美元，毛利20.64百万美元，市盈率-5.52倍。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712232324941f6af5&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics, Inc.盘中异动 快速下挫5.12%报1.21美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics, Inc.盘中异动 快速下挫5.12%报1.21美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-12 23:23 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712232324941f6af5&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>北京时间2024年07月12日23时23分，Akebia Therapeutics, Inc.（AKBA.us）股票出现波动，股价大幅跳水5.12%。截至发稿，该股报1.21美元/股，成交量237.982万股，换手率1.14%，振幅10.24%。最近的财报数据显示，该股实现营业收入32.61百万美元，净利润-17.99百万美元，每股收益-0.09美元，毛利20.64百万美元，市盈率-5.52倍。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712232324941f6af5&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712232324941f6af5&s=b","article_id":"2450253710","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240712232324941f6af5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2450253710","pubTimestamp":1720797803,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"北京时间2024年07月12日23时23分，Akebia Therapeutics, Inc.股票出现波动，股价大幅跳水5.12%。Akebia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.57%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家全面整合的生物制药公司。消息层面，截至23时23分，《BTIG维持Akebia Therapeutics买入评级，维持目标价5美元》资讯为影响Akebia Therapeutics, Inc.的重要信息。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","LENZ":"Therapeutics","BK4139":"生物科技"},"translate_title":"Akebia Therapeutics, Inc. fell 5.12% to $1.21 in intraday movements","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1,"LENZ":1},"content_text":"北京时间2024年07月12日23时23分，Akebia Therapeutics, Inc.（AKBA.us）股票出现波动，股价大幅跳水5.12%。截至发稿，该股报1.21美元/股，成交量237.982万股，换手率1.14%，振幅10.24%。最近的财报数据显示，该股实现营业收入32.61百万美元，净利润-17.99百万美元，每股收益-0.09美元，毛利20.64百万美元，市盈率-5.52倍。机构评级方面，在所有2家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。Akebia Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.57%。其相关个股中，Qualigen Therapeutics, Inc.、Zura Bio Limited C/Wts (To Pur Com)、Xortx Therapeutics Inc.涨幅较大，Qualigen Therapeutics, Inc.、Clearmind Medicine Inc.、Xortx Therapeutics Inc.较为活跃，换手率分别为3191.16%、94.77%、79.41%，振幅较大的相关个股有Qualigen Therapeutics, Inc.、Xortx Therapeutics Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 (To Pur Com)，振幅分别为147.88%、78.88%、65.30%。Akebia Therapeutics, Inc.公司简介：Akebia Therapeutics Inc是一家全面整合的生物制药公司。该公司的运营部门是开发和商业化针对肾脏疾病患者的新型治疗药物的业务。该公司目前的产品组合包括Auryxia（柠檬酸亚铁），这是一种在美国获得批准并上市销售的药物，用于控制透析依赖型慢性肾脏病成人患者的血清磷水平，并用于治疗非透析依赖型慢性肾脏病成人患者的缺铁性贫血，Vafseo（vadadustat）是一种口服缺氧诱导因子脯氢化酶抑制剂，在日本获得批准用于治疗慢性肾脏病引起的贫血的成人患者，HIF-PH抑制剂处于临床前开发阶段。消息层面，截至23时23分，《BTIG维持Akebia Therapeutics(AKBA.US)买入评级，维持目标价5美元》资讯为影响Akebia Therapeutics, Inc.的重要信息。该信息摘要如下：BTIG分析师Julian Harrison维持Akebia Therapeutics 买入评级，维持目标价5美元。根据TipRanks数据显示，该分析师近一年总胜率为48.2%，总平均回报率为12.6%。总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2450253710"}

Akebia Therapeutics, Inc.盘中异动 快速下挫5.12%报1.21美元

精彩评论

Akebia Therapeutics, Inc.盘中异动快速下挫5.12%报1.21美元